
Cidara Therapeutics (CDTX) Stock Forecast & Price Target
Cidara Therapeutics (CDTX) Analyst Ratings
Bulls say
Cidara Therapeutics Inc is positioned favorably due to a strong influenza season reported by the CDC, which indicates a sustained high demand for therapeutic options like CD388. The company has effectively secured funding of $240 million, enabling continued clinical development and rapid progression of CD388, which is perceived to have superiority over traditional vaccines as it does not rely on the immune system. These factors collectively highlight a promising uptake potential for CD388, supported by significant clinical data, which may lead to improved financial performance for the company in the upcoming periods.
Bears say
Cidara Therapeutics reported a significant net loss of $52.4 million for the fourth quarter of 2024, translating to a loss of $5.38 per share, highlighting ongoing financial challenges. The company's lead asset, CD388, despite its strong potency against influenza A and B, suffers from poor oral bioavailability and rapid renal clearance, raising concerns over its clinical usability. Additionally, Cidara's lack of a proven track record of profitability, combined with the potential for future candidates to fail in meeting efficacy and safety benchmarks, further exacerbates the uncertainties surrounding its commercial viability.
This aggregate rating is based on analysts' research of Cidara Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Cidara Therapeutics (CDTX) Analyst Forecast & Price Prediction
Start investing in Cidara Therapeutics (CDTX)
Order type
Buy in
Order amount
Est. shares
0 shares